BiomX Inc (PHGE) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to...

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...

BiomX Announces a Mandatory Unit Separation

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...

BiomX to Present Positive Phase 1b/2a Clinical Trial Data for BX004 at the European Respiratory Society (ERS) Congress 2024

GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...

Form 8-K - Current report

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth...

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

BiomX anticipates reporting important results in 2025 for two clinical assets from the Company’s leading phage...

BiomX Inc. Announces 1-for-10 Reverse Stock Split

GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]